GangaGen is developing a pipeline of ectolysins to target areas of high unmet need.
Ectolysins are different from traditional antibiotics. They act very rapidly to lyse bacteria and therefore have low potential for developing resistance. Each ectolysin is specific to the type of bacteria for which it is developed and leaves other beneficial bacteria unaffected. This means that ectolysins can work on drug resistant bacteria or when the bacteria are not active, such as in hard-to-treat biofilms.
GangaGen’s lead ectolysin, P128, is specific to Staphylococci, including methicillin-resistant strains of Staphylococcus aureus (MRSA) as well as coagulase-negative Staphylococci.
Antibiotic-resistant infections are an increasing public health concern, both in hospitals and in the community, and new classes of antimicrobial agents with different mechanisms of action are urgently required. According to estimates, antibiotic-resistant bacteria cause 23,000 deaths each year in the United States and 25,000 in Europe.
GangaGen is addressing two very serious areas of antibiotic resistance: Staphylococcus aureus and Coagulase-negative staphylococci (CoNS).
S. aureus causes a range of illnesses including life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, bacteremia, and sepsis. S. aureus is one of the most common causes of hospital acquired infection and post-surgical wound infection.MRSA has been recognized as a priority pathogen by the World Health Organisation and the need for new treatments is being given significant priority.
Coagulase-negative Staphylococci have been identified as a major cause of foreign body-related infections, especially catheter-related blood stream infections . These infections are responsible for significant human morbidity, mortality and economic loss throughout the world. Because of involvement of biofilms, these infections are difficult to treat and are often chronic and recurrent in nature.